Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Blast Crisis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Leukemia, Myeloid, Acute
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

abstract

  • The recommended phase II dose of topotecan with intermediate-dose cytarabine is 4.75 mg/m2/d for high-risk patients and 7.0 mg/m2/d for low-risk patients. The percentage of cells in S phase was important in determining response to treatment.

publication date

  • January 1997

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8996123

Additional Document Info

start page

  • 44

end page

  • 51

volume

  • 15

number

  • 1